Wednesday, September 2, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Sep 1, 2026
Boston Scientific halts sales of angiographic catheters amid 2 serious injuries
background ▾
- •Manufacturing defect in Imager II catheters creates risk of device fragment embolism obstructing blood flow and causing end-organ failure—a life-threatening condition
- •This is the second major safety issue with Imager II catheters in two years, raising questions about Boston Scientific's quality control and manufacturing oversight
- •Monitor for expanded injury reports, customer notification details, financial impact quantification, and potential regulatory actions beyond the early alert
Boston ScientificImager II Angiographic Catheters
→ Read original articlePolicy•STAT News•Sep 2, 2026
Opinion: The next DSM should address the algorithm’s role in eating disorders
background ▾
- •The DSM-6 revision (2030) is an opportunity to formalize social media algorithms and digital exposure as clinically relevant environmental factors in eating disorder assessment, mirroring how clinicians already evaluate family dynamics and trauma.
- •A National Eating Disorders Association survey found 82% of respondents reported social media triggering eating disorder thoughts or behaviors, with clinicians noting patients referencing GLP-1 content and recovery patients experiencing relapse from algorithmic feeds.
- •Monitor DSM-6 development and whether psychiatric professional bodies formally adopt algorithmic exposure as a standard assessment component in eating disorder evaluation.
Policy•STAT News•Sep 1, 2026
Opinion: Diabetes association CEO: What an independent review says happened at the ADA’s controversial June conference
background ▾
- •Independent review found no merit to claims that ADA suppressed critical viewpoints or improperly involved law enforcement at the June conference
American Diabetes Association
→ Read original articlePolicy•Fierce Biotech•Sep 1, 2026
Medtronic recalls reflux monitoring device as 184 serious injuries linked to capsule
background ▾
- •184 serious injuries reported as of August 10 associated with failed deployment mechanics in the Bravo CF capsule, with potential for life-threatening complications including hemorrhaging and airway obstruction
- •The defect stems from a component controlling capsule deployment, potentially exacerbated by operator technique (failure to keep delivery device straight), indicating both design and training/procedural vulnerabilities
- •Monitor whether Medtronic's corrective action resolves the root cause and restores physician/payer confidence in the device; assess impact on Bravo CF market share and whether competitors gain ground in the esophageal pH monitoring market
MedtronicBravo CF
→ Read original articlePolicy•Fierce Biotech•Sep 1, 2026
Novocure hit by cyberattack exposing patient data
background ▾
- •Novocure experienced unauthorized access to information systems exposing over 1,400 patient internal ID numbers and limited identifying data for approximately 50 additional patients, with no compromise to device functionality or operational systems
NovocureBoston ScientificMedtronicOptune Pax
→ Read original articleMarket Access
Market Access•Fierce Biotech•Sep 1, 2026
Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody
background ▾
- •Roche paid $75M upfront for a preclinical trispecific antibody with up to $1.53B total value, signaling confidence in dual B-cell targeting as a differentiation strategy for resistant populations
- •Simcere has now completed six out-licensing deals totaling >$6.1B in potential value in <2 years, establishing itself as a high-volume asset generator partnering with tier-1 pharma
- •Watch for SIM0660 IND filing timeline and clinical trial design; the dual CD79a/CD19 approach targeting treatment-resistant B-cell disease represents a competitive landscape shift requiring close monitoring
RocheSimcere ZaimingSimcere Pharmaceutical GroupSIM0660
→ Read original articleMarket Access•Fierce Biotech•Sep 2, 2026
From his parents’ basement to your medicine cabinet: Absci CEO endeavors to create biotech’s Apple
background ▾
- •Absci's strategic focus is positioning ABS-201 as a platform for iterative drug versions at stable pricing, with theoretical future combinations (e.g., with GLP-1 agents) targeting large underserved markets in hair loss and endometriosis.
AbsciEli LillyABS-201
→ Read original articleMarket Access•Endpoints News•Sep 1, 2026
Health Tech meets AI giants
background ▾
- •Google's Gemini AI now offers Zocdoc appointment booking integration, reflecting broader AI adoption in healthcare scheduling rather than pharmaceutical-specific developments
GoogleZocdoc
→ Read original articleMarket Access•Fierce Biotech•Sep 1, 2026
ArsenalBio sheds most of staff in pivot to in vivo CAR-T
background ▾
- •ArsenalBio terminated all ex vivo CAR-T development and is pivoting to in vivo CAR-T, a more crowded competitive space with limited differentiation messaging provided
- •The company is divesting or seeking partnerships for its clinical-stage assets, including lead program AB-2100, signaling inability to execute on original $325M funding thesis
- •Monitor for asset sale announcements and whether BMS/Regeneron/Genentech partnerships are restructured or dissolved given the strategic reversal
ArsenalBioBristol Myers SquibbRegeneronAB-2100AB-3028AB-7000
→ Read original articleMarket Access•Endpoints News•Sep 1, 2026
Arsenal Biosciences cuts ‘majority’ of staff in move to in vivo CAR-T
background ▾
- •Arsenal Biosciences is executing a second major layoff within ~12 months, cutting the majority of its workforce to focus on in vivo CAR-T development
- •The repeated restructuring suggests financial pressure and/or a fundamental strategic pivot away from previous programs
- •Monitor for funding announcements, partnership developments, or pipeline updates that might clarify Arsenal's sustainability and in vivo CAR-T advancement timeline
Arsenal Biosciences
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Sep 1, 2026
Alumis crushed by midstage lupus flop but plots path to phase 3 for TYK2 inhibitor
background ▾
- •Phase 2b primary endpoint miss in unselected SLE population, but strong responder signal (52.6% response rate) in IFNGS-high subgroup representing ~60% of trial population
- •Alumis pursuing phase 3 with potential biomarker-driven enrollment restrictions (IFNGS-high enrichment or capping IFNGS-low patients), requiring FDA alignment and raising efficacy generalizability questions
- •Watch for FDA feedback on biomarker-enriched phase 3 design and whether IFNGS-high stratification becomes accepted path for TYK2 inhibitor development in SLE; psoriasis regulatory submission remains on track as alternative approval avenue
AlumisTakedaenvudeucitinibzasocitinib
→ Read original articleClinical Trials•Fierce Biotech•Sep 1, 2026
ESC: Alnylam's next-gen silencer sees silver linings after fallout of AZ, Ionis trial in ATTR-CM
background ▾
- •AstraZeneca's Wainua failed to meet primary endpoint when combined with stabilizers in CARDIO-TTRansform, suggesting combination TTR silencer plus stabilizer may not provide additive benefit in heavily treated populations.
- •Alnylam emphasizes mechanistic and trial design differences between Wainua (antisense) and its siRNA assets (Amvuttra, nucresiran), and highlights that Wainua showed nominal benefit in stage 1 ATTR-CM patients despite concomitant stabilizer use.
- •Watch TRITON-CM readout for nucresiran and whether Alnylam's hypothesized benefit in earlier-stage ATTR-CM patients materializes; patient stratification by disease stage is emerging as critical to silencer efficacy claims.
AlnylamAstraZenecaIonisWainua (eplontersen)Amvuttra (vutrisiran)nucresiran
→ Read original articleClinical Trials•Endpoints News•Sep 1, 2026
GSK to launch Phase 3 test of mRNA flu vaccine with newer formulation
background ▾
- •GSK's mRNA flu vaccine formulation showed higher immune responses, warranting Phase 3 advancement
- •This positions GSK in the competitive mRNA vaccine market alongside Moderna and other players developing next-generation flu vaccines
- •Watch for Phase 3 efficacy readout and regulatory interactions that could define the timeline for potential market entry
GSKGSK mRNA flu vaccine
→ Read original articleClinical Trials•Endpoints News•Sep 1, 2026
Novartis' Rhapsido safer than rivals, Phase 3 multiple sclerosis data suggest
background ▾
- •Rhapsido Phase 3 MS data show superior or comparable safety versus competitor BTK inhibitors, positioning the drug for potential market expansion beyond its current pruritus indication
- •BTK inhibitors represent a growing MS treatment class; demonstrable safety advantages could drive payer and physician adoption if efficacy is non-inferior
- •Watch for full Phase 3 efficacy data release, regulatory timeline for MS label amendment, and competitive positioning against established and emerging BTK inhibitor programs in MS
NovartisRhapsidofenebrutinib
→ Read original article